ArticleMaterials horizons2018
An immunological electrospun scaffold for tumor cell killing and healthy tissue regeneration.
Article in Materials horizons, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Immunomodulatory Fibrous Scaffold with Dual Enzyme-Mimic Activities Prevents Postsurgical Tumor Recurrence.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Engineering Nanoparticles and Bioscaffolds for Targeted microRNA Delivery in Cardiovascular Regeneration-A Comprehensive Review.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Review
- PEDOT-Integrated Fish Swim Bladders as Conductive Nerve Conduits.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Electrospun fiber-based immune engineering in regenerative medicine.Smart medicine · 2024Review
- Natural Multifunctional Silk Microcarriers for Noise-Induced Hearing Loss Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Bifunctional bone substitute materials for bone defect treatment after bone tumor resection.Materials today. Bio · 2023Review
- Cryo-shocked cancer cell microgels for tumor postoperative combination immunotherapy and tissue regeneration.Bioactive materials · 2023Article
- Recent development of polymer nanomicelles in the treatment of eye diseases.Frontiers in bioengineering and biotechnology · 2023Review
- Injectable magnetic montmorillonite colloidal gel for the postoperative treatment of hepatocellular carcinoma.Journal of nanobiotechnology · 2022Article
- Emerging polymeric electrospun fibers: From structural diversity to application in flexible bioelectronics and tissue engineering.Exploration (Beijing, China) · 2022Article
- Multifunctional Scaffolds and Synergistic Strategies in Tissue Engineering and Regenerative Medicine.Pharmaceutics · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-based cancer immune therapy has attracted lots of research interest in recent years; however, it is greatly limited by the easy distribution and burst release of antibodies. In addition, after the clearance of the tissue, healthy tissue regeneration is another challenge for cancer treatment. Herein, we have developed a specific immunological tissue engineering scaffold using the agonistic mouse anti-human CD40 antibody (CD40mAb) incorporated into poly(l-lactide) (PLLA) electrospun fibers through the dopamine (PDA) motif (PLLA-PDA-CD40mAb). CD40mAb is successfully incorporated onto the surface of the electrospun fibrous scaffold, which is proved by immunofluorescence staining, and the PLLA-PDA-CD40mAb scaffold has an anti-tumor effect by locally releasing CD40mAb. Therefore, this immunological electrospun scaffold has very good potential to be developed as a powerful tool for localized tumor treatment, and this is the first to be reported in this area.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.